The Japanese generics giant shared its annual results for 2023 in what was a transformative year for the company that included the sale of a subsidiary and government inspections.
Sawai Pharmaceutical has reported an 8% growth in net sales for its 2023 fiscal year ending 31 March 2024, narrowly missing past forecasts of its annual results for the year.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Generics Bulletin reviews global regulatory developments across the world.
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.
Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.
Generics Bulletin reviews global regulatory developments across the world.
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.
